• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nano

tetano

Editor, Senior Moderator
J Med Virol


. 2023 Jun;95(6):e28875.
doi: 10.1002/jmv.28875. Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD

Vincenzo Tragni[SUP] 1 [/SUP], Ivan Mercurio[SUP] 2 [/SUP], Diletta Pia Paoletti[SUP] 2 [/SUP], Angelo Onofrio[SUP] 1 [/SUP], Luna Laera[SUP] 2 [/SUP], Lucas Cafferati Beltrame[SUP] 2 [/SUP], Maria Noemi Sgobba[SUP] 2 [/SUP], Lorenzo Guerra[SUP] 2 [/SUP], Mariateresa Volpicella[SUP] 2 [/SUP], Anna De Grassi[SUP] 2 [/SUP], Gabriella Elia[SUP] 3 [/SUP], Ciro Leonardo Pierri[SUP] 1 [/SUP]



Affiliations
Abstract

Since 2020 the COVID-19 pandemic has led scientists to search for strategies to predict the transmissibility and virulence of new severe acute respiratory syndrome coronavirus 2 variants based on the estimation of the affinity of the spike receptor binding domain (RBD) for the human angiotensin-converting enzyme 2 (ACE2) receptor and/or neutralizing antibodies. In this context, our lab developed a computational pipeline to quickly quantify the free energy of interaction at the spike RBD/ACE2 protein-protein interface, reflecting the incidence trend observed in the transmissibility/virulence of the investigated variants. In this new study, we used our pipeline to estimate the free energy of interaction between the RBD from 10 variants, and 14 antibodies (ab), or 5 nanobodies (nb), highlighting the RBD regions preferentially targeted by the investigated ab/nb. Our structural comparative analysis and interaction energy calculations allowed us to propose the most promising RBD regions to be targeted by future ab/nb to be designed by site-directed mutagenesis of existing high-affinity ab/nb, to increase their affinity for the target RBD region, for preventing spike-RBD/ACE2 interactions and virus entry in host cells. Furthermore, we evaluated the ability of the investigated ab/nb to simultaneously interact with the three RBD located on the surface of the trimeric spike protein, which can alternatively be in up- or down- (all-3-up-, all-3-down-, 1-up-/2-down-, 2-up-/1-down-) conformations.

Keywords: SARS-CoV-2; SARS-CoV-2 variants; antibody receptor interactions; antiviral research; binding affinity; interaction energy prediction; nanobodies; neutralizing antibodies.

 
Back
Top Bottom